What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “ABX196 is a synthetic agonist of invariant Natural Killer T (iNKT) cells”In the company’s words, NCT03897543 on ClinicalTrials.gov
- Tested for
- Carcinoma, Hepatocellular
- Main trialPhase 1/2
- “Open-label, uncontrolled, Phase 1-2 study to evaluate the safety, tolerability, pharmacodynamic effects, and preliminary efficacy of ABX196 administered in combination with nivolumab in patients with hepatocellular carcinoma”In the company’s words, NCT03897543 on ClinicalTrials.gov
- Other names
- Obefazimod
Other drugs for Carcinoma, Hepatocellular
- CadonilimabAkeso · Phase 3
- DurvalumabAstraZeneca · Phase 3
- TremelimumabAstraZeneca · Phase 3
- BudigalimabAbbVie · Phase 2/3
- LivmoniplimabAbbVie · Phase 2/3
- BGB-B2033BeOne Medicines (BeiGene) · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Completed | 14 Apr 2022 | ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026